For institutional investors in Norway

Opportunities in healthcare in 2022

The healthcare sector experienced uneven performance in 2021. Looking ahead, Portfolio Manager Andy Acker believes discounted valuations, innovation and the waning influence of COVID-19 are creating attractive investment opportunities throughout the sector.

Key takeaways

  • COVID-19 has led to swings in healthcare stock returns over the past two years but that could change as the pandemic begins to retreat.
  • In COVID’s wake, we think many stocks now trade at a discount to the value of their underlying companies’ growth prospects.
  • In our view, opportunities can be found throughout the sector, including in biotech where new treatment modalities are revolutionising care; in medical devices where advances in robotic surgery are improving patient outcomes; and in managed care, which is benefiting from expanded government health insurance programmes and a robust job market.
Andy Acker, CFA

Andy Acker, CFA

Global Life Sciences | Portfolio Manager


2 Feb 2022

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors and indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them.

 

Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

 

The information in this article does not qualify as an investment recommendation.

 

Marketing Communication.

 

Glossary

 

 

 

Andy Acker, CFA

Andy Acker, CFA

Global Life Sciences | Portfolio Manager


2 Feb 2022